Turnaround Times
Clinical trial assessment turnaround times for applications assessed since January 2016
Measure |
Percentage |
Number |
Percentage of assessments evaluated within 31 days |
91% |
1330 |
Percentage of assessments evaluated beyond 31 days |
9% |
137 |
This figure is titled 'Clinical trial assessment turnaround times' and is made up of a single pie chart. The turnaround times are measured in calendar days. They do not include the time when additional information is requested from the applicant.
The pie chart is made up of 2 slices. The first slice represents the percentage of assessments evaluated within 31 days which is 92%. The second slice represents the percentage of assessments evaluated beyond 31 days which is 8%.
Systemic Treatment-Quality Based Program Alignment
Distribution of clinical trial assessment outcomes that receive funding for the administration and delivery of systemic treatment through the Systemic Treatment-Quality Based Program (ST-QBP), for applications assessed since January 2016
Measure |
Percentage |
Number |
Aligned to ST-QBP definition of a clinical trial |
94% |
1374 |
Not Aligned to ST-QBP definition of a clinical trial |
6% |
93 |
This figure is titled 'Distribution of clinical trial assessment outcomes that receive funding for the administration and delivery of systemic treatment through Systemic Treatment-Quality Based Program (ST-QBP) and is made up of a single pie chart.
The pie chart is made up of 2 slices. The first slice represents the percentage of assessments aligned to ST-QBP definition of a clinical trial which is 94%. The second slice represents the percentage of assessments not aligned to ST-QBP definition of a clinical trial which is 6%.
Provincial Drug Reimbursement Program Alignment
Distribution of clinical trial assessment outcomes for the purpose of public drug funding, for applications assessed since January 2016
Measure |
Percentage |
Number |
Aligned for the purpose of drug funding |
92% |
1343 |
Partially aligned for the purpose of drug funding |
5% |
78 |
Not aligned for the purpose of drug funding |
3% |
46 |
This figure is titled 'Distribution of clinical trial assessment outcomes for the purpose of public drug funding' and is made up of a single pie chart.
The pie chart is made up of 3 slices. The first slice represents the percentage of assessments aligned for the purpose of drug funding which is 91%.
The second slice represents the percentage of assessments partially aligned for the purpose of drug funding, which is 3%. Some clinical trial applications request assessment for multiple publicly funded cancer drugs where some of the drugs are used in accordance with the existing drug funding policy i.e. "aligned" and some of the drugs are not used in accordance with the existing drug funding policy i.e. "not aligned". These clinical trial assessments are “partially aligned”.
The third slice represents the percentage of assessments not aligned for the purpose of drug funding which is 6%.